Viral load and CD4+ cell count of HIV-1 seropositive subjects on antiretroviral therapy in relation to PT and PTTK

Itodo, Grace Eleojo; Johnson, Uhunmwangho Erhimiatoe; Emelike, Felix Okechukwu; Enitan, Seyi Samson; Ojemudia, Theophilus Idahosa; Aigbogun, Stella Ejodameme

doi:10.21608/mid.2024.284064.1913

	Viral load and CD4+ cell count of HIV-1 seropositive subjects on antiretroviral therapy in relation to PT and PTTK
Microbes and Infectious Diseases
Articles in Press, Accepted Manuscript, Available Online from 10 June 2024
Document Type: Original Article
DOI: 10.21608/mid.2024.284064.1913
View on SCiNiTO
Authors
Grace Eleojo Itodo ¹; Uhunmwangho Erhimiatoe Johnson ²; Felix Okechukwu Emelike ²; Seyi Samson Enitan ³; Theophilus Idahosa Ojemudia ⁴; Stella Ejodameme Aigbogun ⁵
¹Microbiology Department, Federal Medical Teaching Hospital Lokoja, Kogi State, Nigeria
²Department of Medical Laboratory Science, Ambrose Alli University, Ekpoma, Edo State, Nigeria
³Department Of Medical Laboratory Science, Babcock University, Ilishan-Remo, Ogun
⁴Department of Parasitology, Federal College of Veterinary and Medical Laboratory Technology, Vom. Plateau State, Nigeria.
⁵Asokoro District Hospital FCT Abuja, Nigeria.
Abstract
Background: The advent of antiretroviral therapy (ART) has revolutionized HIV treatment, suppressing viral replication and preserving CD4+ T cell counts. Understanding the interplay between viral load, CD4+ cell counts, and coagulation parameters like prothrombin time (PT) and partial thromboplastin time (PTTK) is crucial for optimizing HIV management and addressing potential clotting complications in ART-treated individuals. Aim: The study assessed the viral load and CD4+ cell count in HIV-1 positive individuals undergoing antiretroviral therapy (ART), correlating with prothrombin time (PT) and partial thromboplastin time (PTTK) at the Federal Medical Centre in Lokoja, Kogi State. Methods: A cohort of 200 subjects aged 14 to 65 was randomly assigned to four groups: 100 on ART Type-1 (Zidovudine + Lamivudine + Nevirapine), 30 on ART Type-2 (Lamivudine + Efavirenz + Tenofovir), 50 ART-naïve, and 20 HIV-negative controls. Viral load was determined via polymerase chain reaction (PCR), CD4+ cell count via flow cytometry, and PT/PTTK via assay. Results: The outcome of the study revealed significantly (P=0.015) higher CD4+ cell counts in ART-Type 1 and ART-Type 2 groups compared to ART-naïve, except for the HIV-negative control. Significant (P=0.013) differences in PT were observed among ART groups and controls. Similarly, PTTK showed significant (P= 0.006) differences between ART groups and HIV-negative controls. Significant correlations were observed: PT with PTTK (p = 0.001) and inversely with CD4 count (p = 0.001), and CD4 counts inversely with viral load (p = 0.004). Conclusion: ART-treated HIV+ individuals show higher CD4+ counts and favorable coagulation profiles. Integrating PT/PTTK monitoring in ART management is recommended.
Keywords
Coagulation Parameters; Immune Response; HIV Therapy; Hemostasis Evaluation; Immunological Recovery


Statistics Article View: 216